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Feasibility and acceptability of suicide prevention
therapy on acute psychiatric wards: randomised
controlled trial
Gillian Haddock, Daniel Pratt, Patricia A. Gooding, Sarah Peters, Richard Emsley, Emma Evans, James Kelly,
Charlotte Huggett, Ailsa Munro, Kamelia Harris, Linda Davies and Yvonne Awenat
Background
Suicidal behaviour is common in acute psychiatric wards
resulting in distress, and burden for patients, carers and society.
Although psychological therapies for suicidal behaviour are
effective in out-patient settings, there is little research on their
effectiveness for in-patients who are suicidal.
Aims
Our primary objective was to determine whether cognitive–
behavioural suicide prevention therapy (CBSP) was feasible and
acceptable, compared with treatment as usual (TAU) for in-
patients who are suicidal. Secondary aims were to assess the
impact of CBSP on suicidal thinking, behaviours, functioning,
quality of life, service use, cost-effectiveness and psychological
factors associated with suicide.
Method
A single-blind pilot randomised controlled trial comparing TAU to
TAU plus CBSP in in-patients in acute psychiatric wards who are
suicidal (the Inpatient Suicide Intervention and Therapy
Evaluation (INSITE) trial, trial registration: ISRCTN17890126). The
intervention consisted of TAU plus up to 20 CBSP sessions, over
6 months continuing in the community following discharge.
Participants were assessed at baseline and at 6 weeks and
6 months post-baseline.
Results
A total of 51 individuals were randomised (27 to TAU, 24 to TAU
plus CBSP) of whom 37 were followed up at 6 months (19 in TAU,
18 in TAU plus CBSP). Engagement, attendance, safety and user
feedback indicated that the addition of CBSP to TAU for
in-patients who are acutely suicidal was feasible and
acceptable while on in-patient wards and following
discharge. Economic analysis suggests the intervention
could be cost-effective.
Discussion
Psychological therapy can be delivered safely to patients who
are suicidal although modifications are required for this setting.
Findings indicate a larger, definitive trial should be conducted.
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Suicide is a serious public health problem and major cause of pre-
ventable death. Suicidality (i.e. suicidal thoughts/behaviours) has a
substantial social, personal and economic impact, and on health
service provision. In the UK, acute psychiatric care accounts for
over two-thirds of National Health Service (NHS) costs1 with
nearly a third of deaths by suicide occurring in mental health
patients.2 Between 2005 and 2015, there were 13 576 deaths in the
UK (27% of suicides in the general population) where the individual
had been in contact with mental health services in the 12 months
prior to death.2 Suicidal behaviour is an ongoing, recurring
problem3,4 and hospital readmissions are common.5 The first
week of admission to a psychiatric ward is high risk, with approxi-
mately one-quarter of suicide deaths occurring during this time.6
However, the post-discharge period is also high risk. Data from
the UK National Confidential Inquiry into Suicide and Homicide
by People with Mental Illness (2017) reported that 17% of all
patient suicide fatalities occur during the 3 months following dis-
charge from an acute psychiatric ward.2 Given this high prevalence
in the ward and post hospital discharge period, there is an urgent
need to identify treatments that reduce the likelihood of suicidality
in these settings.
There is evidence supporting the use of psychological treat-
ments for suicidality7,8 and National Institute for Health and
Care Excellence guidelines recommend cognitive–behavioural
therapy (CBT) for the treatment of self-harm.9 Several treatment
approaches have been evaluated.8,10 However, these have not all dir-
ectly treated the suicidal, cognitive processes thought to underpin
suicidality and none have been evaluated within in-patient settings.
One approach that does directly target the underlying psychological
mechanisms that drive suicidality is cognitive–behavioural preven-
tion for suicidality in psychosis.11 Two trials of the approach, one
with people with schizophrenia and one with prisoners who are sui-
cidal showed that the treatment was feasible to deliver and effective
in reducing suicidal ideation and suicide probability.8,12 Given that
there are high levels of suicidality within acute psychiatric wards
and post-discharge, it is important to ascertain whether these treat-
ments can be successfully applied in this population. The primary
objective of this trial was to explore whether cognitive–behavioural
suicide prevention therapy (CBSP) was feasible and acceptable on
acute psychiatric wards. However, we also explored secondary out-
comes of suicide behaviour and ideation, functioning, quality of life,
service use, preliminary cost-effectiveness and other psychological
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variables associated with suicidality. The trial protocol has
been published.13
Method
Design
INSITE (Inpatient Suicide Intervention and Therapy Evaluation,
trial registration: ISRCTN17890126) was a single-blind pilot
randomised controlled trial (RCT) with participants on acute psy-
chiatric wards from one NHS trust in the North West of England,
UK. Seventy participants were recruited, and 51 of these were
randomly allocated to treatment as usual (TAU) alone or to
TAU plus CBSP. Participants were followed up at 6 weeks and
6 months.
The trial used a mixed-methods approach following theMedical
Research Council’s framework for developing complex interven-
tions. This included qualitative evaluations with staff and patients
to inform the delivery of the treatment and to garner their views
on its implementation (reported elsewhere, see Awenat et al14,15)
and the RCT evaluating CBSP is reported here.
Ethics and governance
The INSITE trial was supported by the NIHR Research for Patient
Benefit Programme (PB-PG-1111-26026). The study was approved
by the NRES Committee North West – Lancaster (13/NW/0504)
and was conducted following guidelines of Good Clinical Practice
in accordance with the principles of the Declaration of Helsinki.
The study was carried out in collaboration with the national UK
charity, Samaritans and a local branch affiliated to the national
UK charity, Mind. The trial was overseen by an independent trial
steering committee and a Service User Reference Group with previ-
ous experience of in-patient suicidality who contributed to the
design, execution, analysis and dissemination of the trial.
Inclusion criteria
Participants were included if they were between 18 and 65 years of
age, were in-patients on an acute, psychiatric ward, able to provide
informed consent, experienced suicidal thoughts or behaviours
within the 3 months prior to admission and had sufficient English
language capacity. As the intervention was focused on suicidality
rather than on any specific diagnostic group, diagnosis was not con-
sidered as a necessary inclusion criterion.
Recruitment and randomisation
Recruitment for the trial was from May 2014 to January 2016.
Eligible participants were identified by in-patient ward staff on
eight acute psychiatric wards in one large mental health trust in
the North West of the UK. The wards served both inner-city and
rural areas providing a large diversity in potential participants.
Two wards catered for patients with intensive care psychiatric
needs. The wards were served by multidisciplinary teams and spe-
cialised in caring for adults of working age. The wards delivered
assessment and treatment for a diverse range of mental health con-
ditions, and, included those detained under the Mental Health Act
as well as voluntarily admitted patients during an acute, psychiatric
crisis and did not aim to provide longer-term rehabilitation services.
Participants deemed eligible were provided with an information
sheet and informed consent was taken at least 24 h later.
Following baseline assessment participants were randomly assigned
to, either, TAU or TAU plus CBSP. Randomisation was statistician-
led and pseudorandom, carried out using Sealed Envelope software
(https://www.sealedenvelope.com/) with group stratification by
gender and history of self-harm. Allocation concealment was
ensured as participant randomisation codes were not revealed
until the participant was recruited into the trial.
Participants were followed up by research assistants masked to
treatment allocation at 6 weeks and 6 months following baseline
assessment. Procedures for maintaining masking were used.
Participants were reminded by research assistants not to disclose
their treatment allocation. Where breaches of masking occurred
prior to follow-up appointments (18 breaks in masking were
recorded during the trial), subsequent data collection was allocated
to an alternative research assistant to ensure all data were collected
by masked assessors.
Intervention
The intervention consisted of TAU plus up to 20 CBSP sessions of
up to 1 h duration, over 6 months. Participants who were discharged
continued their sessions in the community. TAU comprised usual
nursing and medical care during the in-patient stay, which included
medication, assessments, reviews and evaluation by the ward team.
Following discharge, TAU was overseen by the appropriate care
professional (for example care coordinator, general practitioner,
psychiatrist) and usually involved medical and multidisciplinary
review and monitoring. The intervention was guided by a detailed
treatment protocol11 refined for use with in-patients by the
authors and pretrial qualitative interviews.
CBSP is a one-to-one psychological therapy that aims to achieve
a detailed understanding of an individual’s experiences of suicidality
and to change the thinking processes involved in the activation,
maintenance and elaboration of suicidal thinking and behaviour
using cognitive–behavioural approaches. It was carried out by clin-
ical psychologists meeting the British Association of Behavioural
and Cognitive Psychotherapies minimum standards for CBT prac-
tice. Treatment fidelity was maintained through adherence to a
detailed treatment protocol and weekly supervision. Therapy ses-
sions were audio-recorded with participant’s permission and rated
by the supervisory team using the Cognitive Therapy Scale for
Psychosis.16
Primary outcomes
The primary outcome was feasibility and acceptability of the inter-
vention. This included uptake and attendance at therapy sessions (a
minimum of ten sessions attended was anticipated to be an accept-
able dose of therapy), attrition (we anticipated a 20% attrition rate)
and therapeutic alliance (using the Working Alliance Inventory17
administered to patient and therapist at session four and end of
therapy).
We also considered the occurrence of research related serious
adverse events. Assessment of specific adverse events and serious
adverse events were identified from the hospital incident reporting
system from randomisation to 6 months follow-up. Anticipated
adverse events were predefined as self-harm, harm to others or
property and absconding without leave. These data were collected
from therapists (uptake and attendance, attrition, therapeutic alli-
ance) and from case notes (specific adverse events) throughout
the trial. Acceptability of the intervention was also assessed
through qualitative interviews and these are reported elsewhere.14,15
Secondary outcome measures
Secondary outcomes measures included suicidal ideation, psycho-
pathology, functioning, service use and psychological measures of
suicide. Measures were completed at baseline, 6 weeks and 6
months (end of treatment).
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Measures of intensity and duration of suicidal ideation, and suicidal
plans and behaviours
Suicidal ideation, suicidal plans and behaviours were as follows.
(a) The Suicidal Behaviours Questionnaire – revised, a four-item
measure used to establish risk of suicide, revised to report on
suicidality in the past 3 months.18 The scale has good reliability
and validity in clinical and non-clinical samples (at baseline
only to assess eligibility).
(b) The Beck Scale for Suicidal Ideation, a 21-item self-report scale
evaluating suicidal ideation, planning and intent over the past
week19 with good reliability and validity.
(c) The Suicide Probability Scale, an 18-item self-report question-
naire assessing future suicide probability with good internal
consistency and test–retest reliability.20
(d) The Beck Hopelessness Scale, a 20-item self-report question-
naire, measuring negative beliefs about the future over 3
domains over a week.21 It is widely used in clinical settings
with good reliability and validity.
(e) A review of clinical records. This review was conducted by a
member of the research team to identify episodes of suicidal
behaviour and related adverse events from case records.
Psychopathology
Psychopathology was assessed using the following scales.
(a) The Positive and Negative Syndrome Scale (PANSS),22 an
interviewer-based scale assessing positive and negative psych-
otic symptoms and general psychopathology with good internal
reliability and concurrent validity. All research assistants on the
trial were trained to conduct PANSS interviews according to a
gold-standard measure used in previous trials.23 Intraclass cor-
relations between gold-standard PANSS total scores and
research assistant’s scores were high (between 0.92 and 0.96).
The ongoing reliability of all research assistants was monitored
throughout the trial.
(b) The Psychotic Symptoms Rating Scales (PSYRATS),24 a well-
validated observer-rated assessment of dimensions of halluci-
nations and delusions with excellent psychometric properties.
(c) The Calgary Depression Scale (CDS)25 is a nine-item observer-
rated measure specifically developed for people with severe
mental health problems with high interrater reliability and dis-
criminant validity.
Functioning
Function was assessed using the Personal and Social Performance
Scale.26 It is an interviewer-rated scale used to assess functioning
over four domains. The scale has good psychometric properties
and is sensitive to differences in social functioning.27
Quality of life
Quality of life was assessed using the World Health Organization
Quality of Life-Brief measure. This is 26- item self-report scale
with good to excellent psychometric properties.28,29
Negative self-appraisals and other psychological variables associated
with suicide
These aspects were assessed using the following measures.
(a) The Defeat Scale,30 a 16-item measure assessing defeat, failed
struggle and low social rank over the past week.
(b) The Entrapment Scale,30 a 16-item, self-report scale used to
assess feelings of being trapped by internal and external
events over the past week. The entrapment and defeat measures
both have good psychometric properties.
(c) The Self-Concept Questionnaire,31 a self-report measure of
seven components of self-esteem with high reliability and
good concurrent and discriminant validity.32
(d) Coping in Stressful Situations Scale,33 a 48-item measure asses-
sing three types of coping styles with excellent psychometric
properties.
Health economic measures
The following health economic measures were used.
(a) The EQ-5D-5L,34 which assesses five domains of mobility, self-
care, usual activity, pain/distress and anxiety/depression.
Health status profiles were converted into utility values using
utility tariffs for EuroQoL to estimate quality-adjusted life-
year’s (QALY).34
(b) The Use of Services Inventory. This is a trial-specific data-cap-
turing interview evaluating service use, supplemented by case-
note review used to estimate costs. Service use information was
collected from 6 months before to 6 months after participant
randomisation.
We also collected data on sleep, and patient and staff perceptions of
acute in-patient wards, which will be reported separately.
Clinical data analysis
Wereport all participant flow in accordancewith theCONSORT state-
ment.35 Demographic data were described using summary statistics.
The main efficacy analysis of secondary outcomes was on an inten-
tion-to-treat basis with available data from all participants. Pro-
rating across scales was used if less than 20% of the items were unob-
served, otherwise they were considered as missing. Descriptive statis-
tics were used to summarise quantitative primary outcome data. The
secondary outcome measures were analysed using a linear regression
model, with baseline measurement of outcome, treatment assignment
and site as covariates, at each assessment point separately. The coeffi-
cient of the treatment assignment is an estimate of the between-group
treatment effect, and can inform potential effect sizes for a future
definitive trial. Point estimates and associated 95% confidence intervals
are reported rather than tests of statistical significance (P-values).
Cost-effectiveness analysis
The costs were estimated by multiplying each item of health and
social care service use by its unit cost. The unit costs for each type
of service used were derived from national databases (price year
2015–16).36–38 The main measure of health benefit was the QALY.
Utility values were estimated from the EQ-5D-5L at baseline and
follow-up, using published tariffs;34 QALYswere estimated from sur-
vival and health state utilities. The net costs and QALYs of the CBSP
intervention, compared with TAU, were estimated from the perspec-
tive of the NHS and social care (costs) and patients (QALYs), for a
6-month time horizon. The primary economic outcome was the
incremental cost per QALY gained by the CBSP intervention.
Multiple imputation (predictive mean matching, chained equa-
tions, 10 imputations) imputed missing data. Descriptive statistics
summarised the total costs and QALYs associated with usual care
and the CBSP intervention. Regression models estimated the net
costs (GLM – general linear model, gamma, log) and QALYS
(OLS – ordinary least squares) of CBSP. The regression included
participant demographic characteristics, baseline costs and the
EQ-5D visual analogue scale as well as baseline clinical status.
The net cost and QALY estimates from the regression analyses
were bootstrapped to simulate 10 000 pairs of net cost and net out-
comes. These simulations explored the probability that CBSP may
be cost-effective compared with usual care alone. In line with this
approach, no statistical tests of differences in mean costs or
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outcomes were conducted, although 95% confidence intervals
around the differences are presented.
Results
Participants
In total, 178 potentially eligible patients were referred. Of those, 127
were identified as ineligible, declined to participate, lacked capacity/
interest or were lost before randomisation (Fig. 1). There were 70
individuals who gave consent to take part although only 51 partici-
pants were randomised because some were discharged before base-
line assessment could commence, or these individuals withdrew
following consent but before randomisation. Demographic and
diagnostic data are presented in Table 1. There was a range of
psychiatric diagnoses and/or clinical presentations recorded in
case notes with many people receiving multiple diagnoses.
Therapy attendance and uptake
Data on therapy uptake and attendance are shown in Table 2. The
vast majority of participants were first seen on in-patient wards and
finished therapy in the community. A mean of 6.24 sessions (s.d. =
6.75) were delivered in the in-patient setting with an average of 8.18
sessions (s.d. = 6.53) delivered in the out-patient setting (range 0–20
sessions).
The average number of sessions attended was just over half of
those offered, which was above the ten sessions anticipated to be
acceptable. As can be seen from the range, this varied greatly,
although 62% achieved a minimum of ten sessions and 86%
Referred as potentially eligible
(n= 178)
Randomised
(n= 51)
• Ineligible (n = 45)
• Declined to
 participate (n = 56)
• Unsure about
 capacity/interest (n = 7)
• Lost/dischargedbefore
 randomisation (n = 19)
• Withdrew (n= 1)
• Deceased (n= 1)
• Unable to contact (n= 2)
• Does not want to talk about
 mental health  (n= 1)
• CNA/DNA and unable to contact
 (n= 2)
• Did not want to take part in 6-week
 follow-up as too much was going on (n= 1)
• Lost to follow-up (n= 8)
Allocated to TAU + CBSP
(n= 24)
• Withdrew (n= 4)
• Deceased (n= 1)
• Did not want to speak to research team (n= 1)
• Unable to contact (n= 2)
• DNA and unable to contact (n = 2)
• Unable to contact (n= 1)
• Withdrew (n= 1)
• Did not want to speak to research team (n= 2)
• Withdrew (n= 1)
• Unable to contact (n = 4)
• Multiple CNA and overdue (n= 1)
• Lost to follow-up (n= 6)
Allocated to TAU
(n= 27)
Allocation
6-week follow-up
Complete (n= 19)
6-month follow-up
Complete (n= 19) Complete (n= 18)
Complete (n= 18)
Fig. 1 CONSORT diagram to demonstrate participant flow throughout the trial.
TAU, treatment as usual; CBSP, Cognitive Behavioural Suicide Prevention therapy; CNA, could not attend; DNA, did not attend.
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achieved at least five sessions. Therapy attrition rates were difficult
to ascertain because of this variability; however, non-attendance
rates were low with an average of 1.83 sessions (range 0–9 sessions)
not attended without reason.
Therapeutic alliance (as measured by theWAI), was collected at
session 4 and at the end of therapy. However, the completion rate at
end of therapy for patients was poor so only data from session 4 is
reported here. The therapeutic alliance was similar to that achieved
in other psychological intervention trials with complex clients. As is
typical, patients rated the therapeutic alliance slightly higher than
the therapist (mean 67.16 (s.d. = 10.02) v. mean 62.41 (s.d. =
10.20), t(37) = 1.46, P = .077). Qualitative interviews indicated that
both staff and patients viewed the intervention as welcome and
acceptable in the form in which it was delivered. See Awenat
et al14,15 for a detailed report of these findings.
Serious adverse events
As expected, serious events such as self-harm were common with a
total of 255 serious adverse events recorded during the 6-month
period of treatment for participants. None were deemed to be
research related. There was a large range within participants but
no significant differences in the number of these events between
TAU and CBSP plus TAU, which totalled 150 (median 1, range
105) and 105 (median 2, range 22), respectively.
Secondary outcome measures
Descriptive statistics
Descriptive data at baseline, 6 week and 6 months for all secondary
outcomes are shown in Table 3, and supplementary Tables 1 and 2
available at https://doi.org/10.1192/bjo.2018.85.
Outcomes
No significant differences were observed between the TAU group
and TAU plus CBSP group on any secondary outcome measures,
across all assessment time points. However, it is noteworthy that
raw mean and standard deviation scores for the TAU plus CBSP
group show improvements in suicidal ideation, suicide probability,
functioning, quality of life, some symptoms of psychosis and
depression.
Cost-effectiveness analysis
Overall 57% (29/51) of participants had complete costs and QALY
data (CBSP n = 12/24; TAU n = 17/27). Supplementary Table 3
summarises utility and costs at baseline and 6-month follow-up.
Supplementary Table 4 summarises costs and utility for the multi-
ple imputation data-set. Using the imputed data, the average
cost for the TAU group was £35 925 (standard error (s.e.) =
£6390, 95% CI £23 050–48 800). This appears higher than the
costs of the TAU plus CBSP group (mean £28 566 (s.e. = £6027,
95% CI £16 400–40 733). The average QALY was 0.48 (s.e. =
0.03, 95% CI 0.43–0.54) for the TAU participants, compared with
0.46 (s.e. = 0.03, 95% CI 0.40–0.52) for the people in the TAU
plus CBSP group. However, the 95% confidence intervals of
the two groups overlap, suggesting no difference in either costs
or QALYs.
After taking baseline demographic and clinical characteristics
into account and adjusting for the non-normal distribution of
costs, the bootstrapped analysis indicates that TAU plus CBSP
was associated with a net saving of £15 201 (s.e. = £12 305, 95% CI
−£39 318; £8915) and net loss in QALYs of 0.04 (s.e. = 0.03, 95%
CI −0.10 to 0.03). The 95% confidence intervals cross zero, suggest-
ing these differences are not statistically significant. Despite the high
level of variance in the cost and the QALY, the cost-effectiveness
acceptability analysis suggested that TAU plus CBSP may be cost-
effective. If policymakers are prepared to accept a net saving of
£30 000 for a loss of 1 QALY, then the probability TAU plus
CBSP is cost-effective may be around 90%. The net benefit statistic
indicates a net benefit of £18 002 (s.d. = £12 632, 2.5th and 97.5th
percentiles −£7044 and £42 402, respectively) but the 2.5th and
97.5th percentiles demonstrate uncertainty about the overall cost-
effectiveness of TAU plus CBSP.
Discussion
The issue of suicidal behaviour on acute wards
Acute psychiatric wards are known to be complex and challenging
environments for staff and patients. Recent reports from the
Royal College of Psychiatrists,39 the Care Quality Commission40
Table 1 Demographic characteristics of the participants
Characteristic
TAU
(n = 27)
CBSP + TAU
(n = 24)
Gender, n (%)
Women 15 (56) 14 (58)
Men 12 (44) 10 (42)
Legal status, n (%)
Informal 15 (56) 14 (58)
Section 2 6 (22) 5 (21)
Section 3 6 (22) 5 (21)
Ethnicity, n (%)
White British 23 (85) 21 (88)
White other 2 (7) 1 (4)
Black British 1 (4) 1 (4)
Black other 0 1 (4)
Mixed race 1 (4) 0
Marital status, n (%)
Single 21 (78) 17 (71)
Married/relationship 4 (15) 4 (17)
Divorced/widowed 2 (7) 3 (13)
Employment, n (%)
Unemployed 18 (67) 22 (92)
Volunteering 0 1 (4)
Full-time paid employment 1 (4) 0
Sick leave (from work or education) 8 (29) 1 (4)
Case-note recorded diagnosis,a n (%)
Schizophrenia spectrum 15 (56) 10 (42)
Depression 6 (11.8) 8 (15.7)
Anxiety disorder 1 (2) 2 (3.9)
Post-traumatic stress disorder 1 (2) 0
Obsessive–compulsive disorder 1 (2) 1 (2)
Eating disorder 1 (2) 1 (2)
Substance misuse 4 (7.8) 3 (5.9)
Adjustment disorder 1 (2) 0
Attention-deficit hyperactivity disorder 0 1 (2)
Emotionally unstable personality disorder 6 (22) 11 (46)
Unspecified personality disorder 21 (78) 13 (54)
Age, mean (s.d.) 37.04 (12.41) 33.88 (12.18)
Number of admissions,b median (IQR) 1.5 (2) 2 (3)
TAU, treatment as usual; CBSP, Cognitive Behavioural Suicide Prevention therapy; IQR,
interquartile range.
a. There was some overlap between diagnosis.
b. Total n for data on admissions was 26 for TAU and 21 for the CBSP + TAU group.
Table 2 Therapy uptake
Mean (s.d.) Range
Total number of therapy sessions attended 11.35 (6.46) 0–20
Total number of therapy sessions cancelled 5.21 (3.65) 0–14
Total number of therapy sessions not attended 1.83 (2.65) 0–9
Average therapy session length (minutes) 52.05 (8.93) 32–70
Total appointments arranged 18.35 (6.36) 0–25
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and the Schizophrenia Commission41 highlight low qualified staff/
patient ratios, overreliance on agency workers where staffing is
poor, lack of skills in care and insufficient clinical supervision
and training. Qualitative research with staff delivering care for
suicidal patients14 also reflects these issues, reporting that, witnes-
sing suicide fatalities, as well as, repeated suicidal behaviours in
in-patient settings is a frequent occurrence. The experience can
have a persistent and significant negative impact on staff as well
as on the individual patient and their carers. A study with
acute, psychiatric in-patient staff identified that 49% were emo-
tionally exhausted, with 29% showing significant psychological
distress.42 Current ward procedures that are aimed at minimising
the occurrence of suicidal behaviours on in-patient wards, such as
risk assessments and one-to-one monitoring of adverse beha-
viours can result in a few opportunities for staff to engage patients
in psychosocial interventions.
Main findings
This preliminary study, however, shows that evidenced-based psy-
chological interventions can be implemented successfully in acute
in-patient settings with patients who are perhaps the most dis-
tressed and challenging of all mental health patients, providing
the opportunity for new treatment options that staff can employ.
The trial showed that the intervention and the trial could be deliv-
ered with limited harm i.e. no adverse events were found to be trial
related suggesting that the methods employed in this trial are feas-
ible for the future roll-out of a large-scale RCT.
Challenges of delivering the intervention
Nevertheless, there are challenges to delivering the intervention.
The take-up of therapy was extremely variable. Not everyone
wanted therapy (just over half of those eligible agreed to take
Table 3 Baseline secondary outcomes
Outcomes
TAU, mean (s.d.); n CBSP + TAU, mean (s.d.); n Total, mean (s.d.); n
(n = 27) (n = 24) (n = 51)
Suicide Probability Scale (SPS)
SPS hopelessness 32.19 (7.76); 27 33 (7.62); 24 32.57 (7.63); 51
SPS ideation 29.26 (8.02); 27 28.5 (8.99); 24 28.9 (8.41); 51
SPS negative evaluation 20.86 (4.13); 27 21.79 (3.43); 24 21.3 (3.8); 51
SPS hostility 17.56 (5.68); 27 17.67 (5.83); 24 17.61 (5.69); 51
SPS total 99.86 (19.83); 27 100.96 (21); 24 100.38 (20.19); 51
SPS probability 84.41 (19.4); 27 83.46 (19.75); 24 83.96 (19.37); 51
SPS suicide risk 3.7 (0.72); 27 3.67 (0.64); 24 3.69 (0.68); 51
Beck Scale for Suicidal Ideation Severity
Suicidal 21.03 (9.31); 21 23.6 (8.02); 20 22.3 (8.69); 41
Non-suicidal 0.4 (0.89); 5 0.25 (0.5); 4 0.3 (0.71); 9
Missing 1 0 1
Beck Hopelessness Scale total 13.96 (5.82); 26 14.46 (5.64); 24 14.2 (5.68); 50
RSCQ (self concept questionnaire) total 81.88 (31.08); 26 72.91 (24.85); 23 77.67 (28.4); 49
Defeat scale total 50.42 (11.08); 26 51.21 (8.73); 24 50.8 (9.93); 50
Entrapment scale
External Entrapment scale 26.19 (9.52); 26 26.33 (6.2); 24 26.26 (8.02); 50
Internal Entrapment scale 18.31 (6.4); 26 20.96 (3.21); 24 19.58 (5.25); 50
Entrapment total scale 44.5 (15.23); 26 47.29 (8.37); 24 45.84 (12.38); 50
World Health Organization Quality of Life – Brief measure (WHOQOL)
WHOQOL Item1 2.5 (1.1); 26 2.21 (0.83); 24 2.36 (0.98); 50
WHOQOL Item2 2.38 (1.2); 26 2 (0.78); 24 2.2 (1.03); 50
WHOQOL Dom1 11.19 (2.8); 26 10.29 (2.45); 24 10.76 (2.65); 50
WHOQOL Dom2 8.05 (3.64); 26 6.86 (2.22); 24 7.48 (3.07); 50
WHOQOL Dom3 9.97 (4.81); 26 10.2 (4.47); 23 10.08 (4.61); 49
WHOQOL Dom4 11.35 (1.91); 26 10.38 (2.74); 24 10.88 (2.37); 50
SCI (sleep condition indicator) total 9.77 (7.39); 26 7.43 (5.65); 23 8.67 (6.67); 49
Coping in Stressful Situations Scale (CISS)
CISS1 task 43.57 (12.76); 21 37.6 (12.16); 15 41.08 (12.69); 36
CISS2 emotion 60.48 (8.77); 21 57.4 (9.89); 15 59.19 (9.25); 36
CISS3 avoidance 41.43 (13.67); 21 37.73 (11.5); 15 39.89 (12.77); 36
CISS4 distraction 21 (6.91); 21 19.53 (7.43); 15 20.39 (7.06); 36
CISS5 diversion 13.19 (5.71); 21 11.53 (4.39); 15 12.5 (5.2); 36
Personal and Social Performance Scale (PSP)
PSP activities 4.22 (0.7); 27 4.21 (0.88); 24 4.22 (0.78); 51
PSP relationships 3.63 (0.84); 27 3.63 (1.01); 24 3.63 (0.92); 51
PSP self-care 2.37 (1.31); 27 3.33 (1.55); 24 2.82 (1.49); 51
PSP aggression 2.11 (1.09); 27 2.38 (1.35); 24 2.24 (1.21); 51
PSP total 43.26 (11.27); 27 39.08 (10.91); 24 41.29 (11.19); 51
Psychotic Symptoms Rating Scale (PSYRATS)
PSYRATS hallucination 13.87 (15.86); 23 12.41 (15.85); 17 13.25 (15.67); 40
PSYRATS delusions 9.62 (9.11); 21 10.06 (9.31); 17 9.82 (9.08); 38
Positive and Negative Syndrome Scale (PANSS)
PANSS total 70.63 (15.97); 27 76.08 (17.04); 24 73.2 (16.55); 51
Positive PANSS 15.81 (5.7); 27 16.71 (5.93); 24 16.24 (5.77); 51
Negative PANSS 16.19 (6.31); 27 18.58 (6.53); 24 17.31 (6.47); 51
General PANSS 38.74 (7.78); 27 40.83 (8.17); 24 39.73 (7.96); 51
Calgary Depression Scale total 14.22 (5.59); 27 15.08 (4.81); 24 14.63 (5.2); 51
TAU, treatment as usual; CBSP, Cognitive Behavioural Suicide Prevention therapy.
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part), hence the sample may represent only those most motivated to
engage in therapy. Also, of those who did take part, not everyone
was able to engage across multiple sessions. However, such partici-
pants were in the minority, and significant numbers had a substan-
tial dose of therapy despite severe thoughts of suicidality and
exhibiting extreme suicidal behaviours while in hospital. It is
notable, that even within these severely distressed participants, it
was possible to develop a meaningful therapeutic alliance compar-
able with that demonstrated with other studies with people with
severe mental health problems. It was also notable that a substantial
number of the sessions could be carried out in the in-patient phase,
rather than following discharge. The therapeutic alliance has been
shown to be extremely important in engaging individuals in
therapy in other studies, and, crucially, it has been demonstrated
to consistently predict long-term outcomes.43 Further understand-
ing of staff and patients’ views and experiences of therapy will be
crucial to inform a future trial and how this may influence long-
term outcomes. In addition, exploration of how this has an
impact on staff morale is particularly important.
Limitations
The study had some limitations at should be taken into consider-
ation when interpreting the findings. The study was relatively
small and restricted to one, large mental health trust in the North
of England. This may limit the generalisability of the findings.
However, recruitment took place over a large geographical area
over several in-patient wards. The area represented urban and
rural catchment areas, with considerable social and economic chal-
lenges. In addition, although the psychological therapists who deliv-
ered the intervention were not part of the in-patient ward usual
treatment team, it was not possible for people receiving both arms
of the intervention to be on different wards. This could have led
to some cross contamination of approaches. Related to this, the
intervention could not entirely take place in isolation of the other
treatments that were being delivered on the ward, because therapist
contact with ward staff was essential to communicate risk and to
support ward staff in facilitating the delivery of the intervention.
This may have led to contamination of treatment conditions
through staff adopting interventions with other patients who were
in the TAU arm. Although this study attempted to minimise this,
future studies should ensure that fidelity to the treatment is formally
assessed.
The cost-effectiveness results show high levels of variance and
uncertainty, likely because of the low sample size and the low
numbers of people with complete cost and QALY data. Using the
mean cost and QALY data above and assuming a shared standard
distribution (QALYs: 0.13; costs: £32 015), initial sample size esti-
mates for a simple RCT design suggest that at the 5% significance
level and 80% power, 598 participants would be required to detect
a statistically significant difference in costs. For QALYs, this
sample doubles to 1310. Further work is needed to explore
whether the utility values and estimated QALYs are likely to dis-
criminate between groups, and, how this might relate to other
outcomes for example ward environment and staff well-being.
Implications
Despite these limitations, the study has clear strengths, such as a
well-defined protocol, masked outcome assessment, rigorous statis-
tical and cost-effectiveness analyses and reliable assessors of
outcome. Findings suggest that psychological interventions should
be rigorously evaluated in in-patient settings as they offer a way
forward in improving the care of patients who are suicidal.
The methods used in this study would be appropriate for a larger,
definitive trial.
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